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Controversy exists as to whether minimal change disease
(MCD) and focal segmental glomerulosclerosis (FSGS)
represent different diseases or are manifestations within the
same disease spectrum. Urinary excretion of CD80 (also
known as B7.1) is elevated in patients with MCD and hence
we tested whether urinary CD80 excretion might distinguish
between patients with MCD from those with FSGS. Urinary
CD80 was measured in 17 patients with biopsy-proven MCD
and 22 with proven FSGS using a commercially available
enzyme-linked immunosorbent assay and its molecular size
determined by western blot analysis. A significant increase in
urinary CD80, normalized to urinary creatinine, was found in
patients with MCD in relapse compared to those in remission
or those with FSGS. No significant differences were seen
when CD80 urinary excretion from MCD patients in remission
were compared to those with FSGS. In seven of eight MCD
patients in relapse, CD80 was found in glomeruli by
immunohistochemical analysis of their biopsy specimen. No
CD80 was found in glomeruli of two patients with FSGS and
another MCD patient in remission. Thus, our study supports
the hypothesis that MCD and FSGS represent two different
diseases rather than a continuum of one disease. Urinary
CD80 excretion may be a useful marker to differentiate
between MCD and FSGS.
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Minimal change disease (MCD) is the most common type of
nephrotic syndrome in children and accounts for approxi-
mately 80–90% of cases in thoseo10 years and 50% of cases
in children 410 years.1 The second most common type of
nephrotic syndrome in children is focal segmental glomer-
ulosclerosis (FSGS), which accounts for 10% of all cases in
children.1 Most children presenting with nephrotic syndrome
due to MCD respond to corticosteroid therapy but some are
steroid-dependent or, rarely, steroid resistant.2 In contrast,
most patients with FSGS are relatively resistant to corticos-
teroid therapy.2
The relationship between MCD and primary FSGS has
remained controversial, as some experts have considered the
two entities to represent a continuum of one disease whereas
others consider them separate entities.3 The question is
compounded by those patients who on initial renal biopsy
have been considered to have MCD, but who undergo a
repeat biopsy due to steroid dependence or resistance and are
found to have a lesion that resembles FSGS, often with some
tubular atrophy and interstitial fibrosis. Whether the initial
renal biopsy findings were because of sampling error and may
have missed glomeruli displaying segmental sclerosis remains
open to question. Unfortunately, in most cases, this type of
patient has a slowly progressive deterioration of renal
function, often resulting in renal replacement therapy.4
Proteinuria in both MCD and FSGS appears to be due to a
circulating factor.5,6 Savin et al. have described the presence
of a ‘vascular permeability factor’ in FSGS patients.7 How-
ever, the same authors were unable to detect the presence of
this factor in MCD patients.7
We recently reported significantly elevated levels of CD80
(also known as B7.1) in the urine of subjects with MCD with
active nephrotic syndrome, when compared with the urinary
CD80 levels in healthy subjects and in MCD patients in
remission.8 In our initial report, we also tested small number
of patients with other glomerular diseases, including FSGS,
and found urinary CD80 levels that were similar to those
observed in healthy controls.8 Given these preliminary data,
we tested the hypothesis that urinary CD80 levels may be able
to distinguish MCD from FSGS. We also examined renal
biopsies in a limited number of cases to determine if CD80
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expression is present in podocytes of subjects with MCD and
active nephrotic syndrome.
RESULTS
Demographics, laboratory tests, and immunosuppressive
therapy at the time the urine samples were collected are shown
in Tables 1–3. All patients with MCD in relapse were studied at
the time the diagnosis of relapse was made. All but three of
these subjects were on a tapering dose of immunosuppressive
therapy. For patients in remission, urinary CD80 was measured
at different times after remission. All but two patients in
remission were receiving immunosuppressive drugs at the time
of testing. Five of the FSGS patients were on immunosuppres-
sive therapy at the time of collection (Table 3).
Urinary CD80 excretion in MCD and FSGS
A significant increase in urinary CD80 excretion was
observed in MCD patients in relapse (524±86 ng/g creati-
nine, mean±s.e.m.) when compared with MCD patients in
remission (29±11 ng/g creatinine) (Po0.0001) and to those
with FSGS (57±9 ng/g creatinine) (Po0.001). No statistical
differences in urinary CD80 excretion between MCD patients
in remission and FSGS was found (P¼ 0.64) (Figure 1).
A receiver-operating characteristic curve for urinary CD80
levels comparing MCD in relapse with patients with FSGS
and MCD patients in relapse with MCD in remission are
shown on Figure 2a and b. For MCD in relapse vs FSGS, the
area under the curve was 0.99 and for MCD in relapse vs
MCD in remission, the area under the curve was 1.00.
CD80 is expressed in podocyte in MCD patients in relapse
A limited number of biopsies were available for study,
including seven cases of MCD in relapse, one case of MCD in
remission, and two subjects with FSGS. The only MCD
patient studied during remission of his nephrotic syndrome
was a patient with steroid-dependent nephrotic syndrome
who having suffered multiple relapses underwent a renal
biopsy done after remission was induced. CD80 was present
in the glomeruli of 7 of 7 MCD patients in relapse, but was
minimal or absent in 2 of 2 subjects with FSGS and in the one
subject with MCD in remission. Of the seven MCD patients
in relapse, none showed tubular staining for CD80 (Figure 3).
Figure 4 shows CD80 staining in glomerulus of a patient
with MCD in relapse (Figure 4a), absence of CD80 staining in
glomerulus from MCD patient in remission (Figure 4b) and
minimal segmental CD80 staining in a glomerulus from an
FSGS patient. This latter patient (patient no. 3, Table 3), had
a concomitant urinary CD80 excretion of 75 ng/g creatinine.
Figure 5a and b show two glomeruli from an MCD patient in
relapse stained for CD80 in red (Figure 5a) and podocin in
green (Figure 5b). Figure 5c and d shows a glomerulus from
an MCD patient in relapse stained for CD80 with double
immunostaining for CD80 and podocin that shows co-
localization (Figure 4d).
Urinary CD80 is cell membrane-associated. Western
blotting was performed of urine proteins in patients with
MCD to determine if the CD80 was soluble CD80 (MW
23 kDa) or membrane-associated CD80 (MW 53 kDa). The
molecular weight of the CD80 in patients with active or
Table 1 | Demographic, laboratory data, and therapy for MCD patients in remission
Patient
Age
(years) Gender
Urinary sCD80
(ng/g creat)
Serum albumin
(g/dl)
Up/Uc ratioa
(or dipstick) Treatment
1 20 F 25 4 0.05 Prednisone 60mg QD
Tacrolimus 2mg BID
Mycophenolate mofetil 500mg BID
2 3 M BLDb NAc 0.34 Prednisone 24mg QOD
3 3 F 150 NA 0.22 None (off steroids for 3 weeks)
4 2 M 33 NA Neg Prednisone 36mg QOD
Cyclosporin 30mg BID
5 13 M 12 NA 0.1 Prednisone 30mg QOD
6 8 F 2 NA 0.17 Prednisone 15mg BID
7 3 M BLDb NA Neg Prednisone 24mg QD
8 5 F BLDb NA Neg Prednisone 15mg QOD (tapering)
9 4 M 6 NA Neg Prednisone 6mg QOD
Cyclosporin 40mg BID
10 3 F 12 2.7 Trace Prednisone 12mg QOD
Mycophenolate mofetil 340mg BID
Tacrolimus 1mg BID
11 10 M 65 NA 0.17 Prednisone 40mg QD
Cyclosporin 75mg BID
12 1 M 48 NA 100mg% Prednisone 30mg QOD
13 5 F 71 NA Neg Prednisone 8ml QOD
Cyclosporin 75mg BID
14 3 M 10 NA 0.24 None
15 14 F BLDb NA Cyclosporin 100mg BID
Mycophenolic acid 360mg BID
Mean±s.e.m. 6.5±1.4 29±11 0.18±0.03
aUp/Uc, urinary protein/urinary creatinine.
bBLD, below limit of detection.
cNA, not available.
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relapsing MCD was 53 kDa, consistent with the cell
membrane-associated CD80 (Figure 6).
DISCUSSION
We tested the hypothesis that urinary CD80 excretion can
distinguish MCD from FSGS. The hypothesis was based on
our previous study in which we had found elevated levels of
CD80 in the urine of subjects with MCD in relapse.8 This
study confirms the preliminary finding of an increased CD80
urinary level in MCD patients in relapse.8 In contrast, urinary
CD80 was not increased in any of the FSGS subjects. These
data suggest that urinary CD80 represents a robust marker
that may be able to distinguish MCD in relapse from FSGS
and therefore may be useful as a diagnostic marker.
The molecular weight of CD80 in the urine was shown
to be 53 KDa, consistent with the CD80 being the whole
cell membrane-associated CD80 (ref. 9) as opposed to the
circulating 23 kDa soluble CD80 that is known to be secreted
by circulating B cells.10,11 In addition, while tubular cells and
dendritic cells can express CD80, the immunofluorescence
studies in subjects with active MCD documented that CD80
was almost exclusively localized to podocytes with negative
staining outside the glomerulus. Thus, these studies suggest
that the source of the urinary CD80 is the podocyte.
Recently a role for podocyte CD80 has been shown in
several experimental models of proteinuria.12 Increased
expression of CD80 in podocytes has been found in genetic,
drug-induced, immune-mediated, and bacterial toxin-
induced experimental kidney diseases with nephrotic syn-
drome.12 In turn, CD80 expression in cultured podocytes has
been shown to result in a decreased expression of nephrin,
which is critical to maintain the glomerular capillary barrier
to protein.13 Consistent with this observation, the injection
of lipopolysaccharide (LPS) to mice results in proteinuria
and podocyte CD80 expression, but proteinuria fails to
develop if LPS is injected into CD80 knockout mice.12
The mechanism responsible for inducing CD80 in the
podocyte of MCD patients is currently under active study.
One potential candidate is IL-13, which is a cytokine
expressed by activated T cells. IL-13 levels are elevated in
the serum of subjects with MCD, and IL-13 expression is
increased in T cells isolated from these patients.14,15 IL-13
overexpressing rats also develop nephrotic syndrome asso-
ciated with podocyte CD80 expression in which the
histological features resemble MCD.16
We have also postulated that MCD may be due in part to a
defect in the ability of the immune system to turn off
podocyte CD80 expression.8 In this regard, regulatory T cells
produce factors, such as soluble CTLA-4, that can bind to
dendritic cells expressing CD80 and which act to block T-cell
activation.17 Some studies suggest CTLA-4 may also alter
dendritic cell function. We have recently shown that
T regulatory cells are functionally deficient in MCD
subjects,18 and soluble CTLA-4 levels tend to be low in the
serum and urine of subjects with MCD in relapse.8 Hence,
one could postulate that continued stimulation (such as by
IL-13), or ineffective censoring of CD80 expression by
T-regulatory cells may underlie the pathogenesis of MCD.
Although our studies do not prove that the pathogenesis
of MCD and FSGS are different, the data are consistent with
the hypothesis that expression of CD80 by the podocyte may
identify a steroid-sensitive form of MCD and suggest this
entity may be distinct from cases that are steroid resistant
(and who may in effect have an early form of FSGS). The
concept that MCD is distinct from FSGS is also supported by
the studies of Savin et al.,7 who have identified a specific
Table 2 | Demographic, laboratory data, and therapy for MCD patients in relapse
Patient
Age
(years) Gender
Urinary sCD80
(ng/g creat)
Serum albumin
(g/dl)
Up/Uc ratioa
(or dipstick) Treatment
1 19 F 214 2.6 16.2 Prednisone 60mg QD
2 3 M 521 NAb 10 Prednisone 33mg QD
3 4 F 1139 2.5 4.3 None
4 3 M 500 2.4 0.89 Prednisone 3mg QOD
Cyclosporin 20mg BID
5 13 M 737 3.3 6.2 None
6 8 F 201 2.7 7.9 Prednisone 15mg BID
7 3 M 984 NA 5.5 Prednisone 27mg QD
8 5 F 825 NA 3+ None
9 4 M 193 NA 3+ Prednisone 12mg QOD
10 4 F 882 1.3 3+ Prednisone 4.5mg QOD
Tacrolimus 1mg QD
11 11 M 380 1.1 22.7 Prednisone 10mg QOD
Cyclosporin 100mg BID
12 1 M 725 1 10.37 Prednisone 30mg QOD
13 5 F 200 2 3+ Prednisone 36mg QOD
Cyclosporin 75mg BID
14 6 M 158 1.5 3+ Prednisone 39mg QD
15 3 M 198 NA 3+ Prednisone 20mg QOD
Mean±s.e.m. 6.1±1.2 524±86 2.2±0.3 7.7±2.2
aUp/Uc, urinary protein/urinary creatinine.
bNA, not available.
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factor they believe may be responsible for some cases of FSGS
as opposed to MCD.
Historically FSGS has been difficult to distinguish from
MCD as early in its course FSGS may not be associated with
glomerular sclerosis.3 This has best been shown in subjects
with FSGS who relapse immediately following transplant-
ation, in which the renal biopsy shows a lesion that resembles
MCD.19 This should not necessarily be viewed as surprising,
as the proteinuria in subjects with FSGS is known to be due
to a generalized glomerular capillary wall defect as noted by
the foot process fusion observed by electron microscopy.
Indeed, the segmental sclerosing lesions are thought to be a
consequence of the prolonged proteinuria, perhaps due to
mesangial activation20,21 or the development of synechiae
with collapse of a segment of the glomerular tuft.22 Our
studies raise the possibility that urinary CD80 may provide a
noninvasive means for distinguishing these two entities.
Sixteen of the FSGS were older than 21 years. Therefore, it
may be argued that the low CD80 levels observed in these
subjects could be the consequence of an increased urinary
creatinine present in adults compared with children rather
than a true low level of urinary CD80 excretion. However, we
believe that the low urinary CD80/creatinine ratios in FSGS
patients are not because of higher urinary creatinine levels
because the urinary excretion of CD80 in MCD patients in
remission (29±11 ng/g creatinine (mean±s.e.m.)) was not
different than the observed excretion in the FSGS patients
who were younger than 21 years (35±6 ng/g creatinine
(mean±s.e.m.)) and, in contrast to what would have been
Table 3 | Demographic, laboratory data, and therapy for FSGS patients
Patient
Age
(years) Gender
Urinary sCD80
(ng/g creat)
Serum
albumin (g/dl)
Up/Uc ratioa
(or dipstick) Treatment
1 18 F 52 4.2 0.56 None
2 15 M 24 NAb 1.5 None
3 14 F 75 3.5 2.5 Prednisone 20mg QOD
Cyclosporin 100mg BID
4 40 F 72 3.6 3+ None
5 23 F 88 4.1 2.2 None
6 17 F 10 2.7 23.6 Prednisone 7mg QD
Mycophenolate mofetil 500mg AM, 700mg PM
Tacrolimus 1mg AM, 0.5mg PM
7 34 F 21 1.6 5.9 Cyclosporin 50mg AM, 25mg PM
Sirolimus 5mg QD
Prednisone 10mg QD
8 26 M 9 2.6 9.8 None
9 25 F 81 1.5 5.4 Prednisone 60mg QD
10 56 M 31 2.3 7.9 Prednisone 20mg QD
Sirolimus 4mg QD
Tacrolimus 0.5mg QD
11 81 F 54 2.3 8.7 None
12 26 F 184 o1.0 30.5 None
13 59 F 65 3.6 4.7c None
14 27 F 142 NA 7.2 None
15 49 F 50 o1.0 5.8 None
16 15 F 32 3.0 4.7 None
17 61 F 5 3.3 3+ None
18 59 F 66 3.8 8.5c None
19 18 M 21 3.4 3+ None
20 30 F 43 3.4 5.3 None
21 48 F 119 2.2 3+ None
22 42 F 58 2.7 4.0 None
Mean±s.e.m. 35.8±3.8 57±9 2.8±0.2 7.9±1.8
aUp/Uc, urinary protein/urinary creatinine.
bNA, not available.
cThese two patients were included among the nephrotic patients because of their rather elevated urinary protein/creatinine ratio.
P < 0.0001 P = 0.064
MCD relapse
MCD remission
FSGS
Urinary CD80
P <0.0001
n
g/
g 
cr
ea
tin
in
e
1500
1000
500
0
MC
D r
ela
pse
MC
D r
em
iss
ion FS
GS
Figure 1 |Urinary CD80 levels in MCD patients in relapse, MCD
patients in remission, and FSGS patients. FSGS, focal segmental
glomerulosclerosis; MCD, minimal change disease.
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expected, the CD80 urinary excretion in those greater than
21 years tended to be higher (68±12 ng/g creatinine
(mean±s.e.m.)) and not lower than those with FSGS who
were less than 21 years (P¼ 0.16). Furthermore, the
remarkable separation of urinary CD80 excretion, coupled
with the differences in immunostaining for CD80 of renal
biopsies, suggests that the differences are likely due to the
disease itself rather than to the age of the subject. Clearly
additional studies by other groups are needed to confirm
these findings.
In conclusion, urinary CD80 excretion is increased in MCD
subjects in relapse but not in FSGS patients and, therefore, may
be useful to distinguish MCD from FSGS. Although more renal
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Figure 2 |Receiver operating characteristic curves for
differentiating MCD and FSGS. ROC analysis of urinary CD80
levels comparing MCD patients in relapse and FSGS (a) and MCD
patients in relapse and remission (b). MCD, minimal change
disease.
Figure 3 |Minimal change disease in relapse. CD80 is present in
glomeruli (red stain) but not in tubules.
Figure 4 |CD80 in glomerulus of minimal change disease and
focal segmental glomerulosclerosis patients. (a) CD80 is
expressed (red stain) in glomerulus from an MCD patient in
relapse. (b) CD80 stain is absent in glomerulus of minimal change
disease patient in remission and (c) minimal segmental stain for
CD80 in patient with focal segmental glomerulosclerosis. Urinary
CD80 excretion in this patient was 75 ng/g creatinine.
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Figure 5 |Co-localization of CD80 and podocin in glomerular
capillary walls. (a and c) CD80 is expressed (red stain) in
glomeruli of two MCD patients in relapse. (b) Podocin is expressed
(green stain) in glomeruli of MCD patients in relapse. (d) CD80 and
podocin co-localize at the glomerular capillary wall.
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biopsy samples need to be tested, our studies would support
the hypothesis that podocyte CD80 expression in the patho-
genesis of proteinuria in subjects with MCD.
MATERIALS AND METHODS
Patients
Seventeen patients with biopsy proven MCD (ages 1–19 years) were
studied. Ten of the 17 patients were also studied in our previous
publication.8 However, data of these 10 patients in this report
originated from different urine samples collected on subsequent
relapses or on follow up evaluations while in remission. No urine
samples from the previous study were rerun. Thirteen were studied
both in relapse and after remission was achieved. Two were studied
only during remission and two only during relapse. All MCD
patients were followed at the University of Florida. Twenty-two
patients with biopsy proven FSGS (ages 14–81 years) were included
in the study (Tables 1–3). Seventeen of these patients presented with
active nephrotic syndrome and five with proteinuria. Three patients
with FSGS were seen at the University of Florida, Gainesville, FL,
USA and 19 at the Medical University of South Carolina.
Definitions
MCD was defined based on renal biopsy findings according to
established criteria by the International Study for Kidney Diseases in
Children.23 FSGS was also defined by renal biopsy findings showing
focal and segmental consolidation of the glomerular tuft with
increased extracellular matrix obliterating the capillary lumen with
or without synechiae and hyalinosis and with either negative
immunofluorescence or only segmental IgM or C3 staining.
Relapse was defined as proteinuria (43.0 urinary protein (mg)/
creatinine (mg) ratio or 3þ or greater by using the tetrabromo-
phenol-citrate buffer colorimetric qualitative dipstick test) and a
serum albumin o3.5 g/dl. Remission was defined as a urinary
protein/creatinine ratioo0.2 (or less than 0.5 for children under the
age of 5 years) and serum albumin 43.5 g/dl). Immunosuppressive
therapy at the time of the study is shown in Tables 1–3.
The study was approved by the Institutional Review Board of the
University of Florida and the Medical University of South Carolina.
Informed consent was obtained from each patient.
Urinary CD80 measurements
Urinary CD80 was measured using a commercially available ELISA
kit (Bender MedSystems, Burlingame, CA, USA) and results
adjusted for urinary creatinine excretion. Urinary creatinine and
protein and serum albumin were measured by an autoanalyzer.
Western blotting and protein extraction
CD80 molecular size was determined by western blot analysis.
Owing to the high level of albumin in some urines, which can
obscure CD80 detection, the protein was analyzed by antibody
precipitation followed by western blot. An amount of patient urine
equivalent to 37 mg creatinine was added to a microcentrifuge tube
and 1 PBS added to a final volume of 1 ml (total protein levels
varied by 268–2394 mg). The diluted urine was first precleared of
rabbit antibody by addition of 20 ml of Protein A agarose slurry
(Roche, Indianapolis, IN, USA) and incubation at 4 1C with gentle
mixing for 2 h. The sample was centrifuged at 6000 g at 4 1C for
2 min and the supernatant transferred to a new tube. A rabbit anti-
human CD80 antibody (1ml, no. NB110-55564, Novus, Littleton,
CO, USA) was added and the sample incubated with mixing at 4 1C
overnight. A 20 ml aliquot of Protein A agarose was added to bind
the antibody and the sample incubated with mixing for 2 h at 4 1C.
The sample was then centrifuged at 13,000 g for 5 min at 4 1C and
the supernatant carefully removed. An equal volume (B30ml) of
2 loading buffer was added to the agarose pellet and the sample
boiled for 5 min, centrifuged at RT at 13,000 g for 5 min and 30 ml of
sample subjected to separation in a 4–20% gradient PAGE. The gel
was transferred to PVDF membrane, blocked and incubated with
Goat anti-human CD80 antibody (2ml, no. AF140, R&D Systems,
Minneapolis, MN, USA) overnight. The membrane was washed and
incubated with a mouse anti-goat HRP-conjugated secondary
antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for
2 h. The blot was visualized using ImmunoStar HRP substrate
(BioRad, Hercules, CA, USA).
Immunohistochemistry
Snap frozen fresh tissues in liquid nitrogen were embedded in OCT
Compound and stored at 80 1C. Tissue sections were cut (4- to
8-mm thick) on a Lecia cryostat and mounted on superfrost plus
(Fisher Scientific) slides. Slides were stored at 80 1C until use.
Before staining, slides were warmed at room temperature for 30 min,
fixed in ice-cold acetone for 5 min and air dried for 30 min.
Subsequently, sections were rinsed in 1 PBS-0.1%Tween 20 twice
for 2 min at room temperature. Sections were incubated in normal
donkey serum blocking solution, and then incubated for 1 h at room
temperature using anti-human polyclonal CD80 goat antibody
(R&D Systems) and rinsed twice with PBS-Tween 20 for 3 min each
time. Antigen–antibody complexes were visualized with donkey anti-
goat IgG-conjugated with red fluorescent 594 dye secondary
antibodies (Alexa Fluor, catalog no. A-11058, Invitrogen, Carlsbad,
CA, USA). Sections were incubated with the secondary antibody for
30 min at room temperature and rinsed with PBS-Tween 20 three
times for 2 min. A cover slip with anti-fade fluorescent mounting
medium containing DAPI was placed and sealed with nail polish.
Slides were examined by immunofluorescence microscopy and
analyzed by Zeiss Image Software. Frozen tissue sections were also
double immunostained for podocin (Santa Cruz Biologicals) with
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Figure 6 |Western blot of CD80 protein in normal urine from
patients with MCD, in remission and relapse. Urine CD80 was
immunoprecipitated to eliminate the interference from albumin
present in some urines and is present as a B53 kDa protein. For
comparison, CD80 from human kidney lysate shows both a 53 and
26 kDa protein. MCD, minimal change disease.
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modifications of a previously published double immunofluores-
cence staining protocol.24
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